A radical new treatment has given some lung cancer patients more than an extra year of life, according to results from the first mass trial.
Nivolumab is one of a raft of immune-boosting drugs which doctors say are having remarkable success in tackling a range of hard-to-treat cancers.
Scientists claim the breakthrough offers 'real hope' to tens of thousands of lung-cancer patients across Britain, with immunotherapy drugs set to become as important as radiotherapy and chemotherapy.
But the drugs are so expensive there are fears they will be turned down for routine NHS use.
No comments:
Post a Comment